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ABSTRACT
THE ASSOCIATION BETWEEN DEPRESSION AND ANXIETY WITH COVID-19
OUTCOMES.
Erica Miller
11/30/2021
Previous studies have shown that mental disorders affect COVID-19 mortality.
This study investigated the effect of depression and/or anxiety on COVID-19 outcomes.
Depression/anxiety was defined by actively taking medication and/or diagnosis. The
outcomes were ICU admission; ventilation; mortality; and time to mortality. Of 698
hospitalized patients, there were 204 (29%) defined to have either depression or anxiety.
There were 109 deaths, and of those, 52 (48%) were diagnosed with depression/anxiety.
Multivariable logistic regression and Cox proportional hazards models were used to
examine associations. ICU admission and ventilation were not significantly associated
with depression/anxiety. Depression/anxiety was associated with mortality (OR: 1.84,
95% CI: 1.15-2.93, p: 0.01) and time to mortality (HR: 1.60, 95% CI: 1.07-2.39, p: 0.02),
adjusting for age, sex, and history of COPD. The association seemed driven by patients
who were never admitted to the ICU. This study showed that depression/anxiety has a
significant effect on COVID-19 mortality.
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I. INTRODUCTION
At the end of 2019, SARS-CoV-2 emerged in Wuhan, China causing coronavirus
disease, COVID-19. Since its emergence, it has created a pandemic. Social distancing
and isolation from others have been recommended practices to prevent and slow the
spread of the virus. These practices may have helped reduce infections, but they may also
have had a negative impact on mental health and resulted in increased depressive
episodes among the affected populations. While there is evidence in the literature
suggesting that COVID-19 is a risk factor for mental disorders, including depression, it is
still not known whether depression prior to SARS-CoV-2 infection is a risk factor for
adverse outcomes from COVID-19. In 2017, prior to the emergence of SARS-CoV-2,
7.9% of the adult population (18 years or older) were reported to have experienced at
least one depressive episode [1]. As of October 20, 2021 there have been over 44,900,000
cases of COVID-19 diagnosed in the United States or around 13% of the total population
[2]. These data demonstrate that both depression and COVID-19 are prevalent within the
United States population, which creates an imminent public health concern.
Depression has been shown to be associated with increased levels of
inflammatory markers including interleukin-6 and C-reactive protein, which may either
increase or decrease the risk of COVID-19 adverse outcomes. Within Kentucky, during
September 29th-October 11th, 2021, 30.9% of Kentucky residents who participated in the
1

Household Pulse Survey conducted by the National Center for Health Statistics reported
symptoms of anxiety disorders and 28.6% reported symptoms of depressive disorder [3].
The objective of this study was to explore the potential association between
depression and COVID-19 severity. Disease severity was measured through mortality,
ventilation, and intensive care unit admission. This study is a retrospective cohort of
individuals hospitalized with COVID-19 in nine different hospitals located in Louisville,
KY. Mortality, ventilation, and intensive care unit (ICU) admission were each measured
dichotomously and analyzed through logistic regression. Time to death was analyzed
using Cox proportional hazards (PH) modeling. This study aimed to fill a gap in the
literature investigating depression as a risk factor for COVID-19 outcomes.
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II. OBJECTIVE, SPECIFIC AIMS, AND HYPOTHESES
The primary objective of the study was to assess the effect of depression and/or
anxiety on COVID-19 severity outcomes and mortality. Effect modification and
mediation by inflammatory markers Interleukin-6 (IL-6) and C-Reactive Protein (CRP)
on depression and/or anxiety on COVID-19 mortality were also evaluated.
The specific aims of the study were:
Specific Aim 1: To evaluate the association between depression and/or anxiety with
COVID-19 severity. For purposes of this study, any patient actively taking depression
medication was defined as having depression. Similarly, in order to be defined as having
anxiety, active anxiety medication use was required, however, unlike for depression, a
diagnosis of anxiety was also required. COVID-19 severity was assessed through
ventilation or ICU admission. Hypothesis: There is a significant association between
depression/anxiety and COVID-19 severity as measured by {1} ICU admission and {2}
ventilation.
Specific Aim 2: To evaluate the association between depression and COVID-19
mortality. Mortality was assessed through discharge status which was either alive or
deceased. Hypothesis: There is a significant association between depression and COVID19 mortality.
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Specific Aim 3: To evaluate if inflammation, assessed through levels of the inflammatory
markers IL-6 and CRP, acts as an effect modifier or mediator on the association between
depression and/or anxiety and COVID-19 mortality. Hypothesis: Inflammation will
modify or mediate the association between depression and COVID-19 mortality.
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III. BACKGROUND AND LITERATURE REVIEW
Depression
Epidemiology and Burden of Depression
Depression is a serious mood disorder defined by experiencing persistent feelings
of sadness and hopelessness and loss in interest in activities one once enjoyed. Other
symptoms that are characteristic of depression include: a depressed mood most of the
day; diminished interest or pleasure in all or almost all activities through the day;
significant weight loss or decrease or increase in appetite; slowing down of thought and
reduction of physical movement; fatigue or loss of energy; feeling worthless or excessive
or inappropriate guilt; diminished ability to think or concentrate; and recurrent thoughts
of death or suicidal thoughts or behavior [3]. Depression can be diagnosed after
experiencing symptoms for at least two weeks. According to the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition (DSM-5), an individual must
experience five or more symptoms during the same two weeks and at least one of the
symptoms should either be depressed mood or loss of interest or pleasure [3]. These
symptoms must cause the individual clinically significant distress or impairment in
social, occupational, or other important areas of functioning [3].
Depression can occur at any age. Diagnoses of depression in children are rare, but
they increase in frequency through adolescence and young adulthood. Childhood
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depression can present as prominent irritability rather than low mood. Many of the
chronic mood and anxiety disorders in adults begin as high levels of anxiety in childhood
[1]. For midlife or older adults, depression is often present as a comorbidity with diseases
like diabetes, cancer, heart disease, and Parkinson’s disease [1]. Such medical conditions
can worsen the severity of depression. Clinically, the earlier the onset of the depressive
episodes, the greater the risk of reoccurrence, chronicity, and impairment [4]. Between
50-80% of those who experience one significant episode will have recurrent episodes and
intermittent subclinical symptoms while the risk of recurrence progressively increases
with each episode [5, 6]. In 2019, among the adults aged 18 and older, females had a
higher prevalence of a major depressive episode (9.6%) compared to males (6.0%) in the
United States [7]. The highest prevalence of a major depressive episode was seen among
adults who reported two ethnicities (13.7%) [7]. Among individuals who reportated a
single ethnicity, it was highest among whites (8.5%) [7]. Adults aged 18-25 years old had
the highest prevalence (15.2%) while adults aged 26-49 had a lower prevalence (8.9%)
and adults aged 50 and over had the lowest prevalence (4.7%) [7].
Etiology of Depression
There are biological and social risk factors that are associated with depression.
Genetics are a predecessor for biological risk factors for depression [8]. The differences
between brain chemical compositions from neurotransmitters are a biological risk factor.
Those who have a family history of depression, have a higher risk of a depression
diagnosis. An individual with a twin diagnosed with depression has a 70% chance of
developing depression [8]. A sleep disorder or serious illness like cancer, heart disease,
6

diabetes, cancer, stroke, or Alzheimer’s disease are all considered biological risk factors
as well [1].
Social risk factors are as prevalent as biological risk factors. Individuals who were
neglected or abused as children have a higher risk for major depression [5]. Women are
more likely to develop major depression compared to men. Women are susceptible to
depression during pregnancy, postnatal care, and menopause [1]. Lack of social support
is another known social risk factor. Feeling excluded or alone can bring on an episode of
depression to individuals who are susceptible to depression or mood disorders [4]. Major
life events such as a new job, job loss, buying a house, divorce, moving, retiring, or
losing a loved one can also trigger depressive episodes. Sadness is part of the grief cycle,
but some people are more vulnerable to not moving out of this stage and this creates a
depressive episode [1]. Abusing certain substances can increase the risk for depression.
These substances include non-prescribed medications, alcohol, and illegal drugs. These
can change the chemical composition of the brain and neurotransmitters linking social
and biological risk factors [9]. Prescribed medications, including blood pressure
medications, sleeping pills, steroids, and painkillers, have been linked to increased risk
for depression like [9].
Pathophysiology of Depression
Human biological components have a distinct relation with depression. Genetic,
neurological, hormonal, immunological, and neuroendocrinological mechanisms are
some of the biological components that relate to depression [4]. Etiologic models that are
based around the diathesis-stress models show which stressful situations trigger
7

depression in those who are predisposed based on biological and psychological
characteristics [4]. Individuals with a first-degree relation to an individual with
depression are 2.5 times more likely to develop major depression [10, 11]. Chronic
stressors may prime the immune system, to make a heightened response to stress. It may
also interfere with the capacity of the immune system to return to baseline after
termination and show a dysregulation in the hypothalamus-pituitary-adrenal axis (HPA
axis) [12]. A longitudinal birth cohort was followed in New Zealand exploring the effects
of early childhood exposure on depression and inflammatory responses [13]. This cohort
was followed into young adulthood and compared those without depression and without
childhood maltreatment, those with depression and no maltreatment, those without
depression and with maltreatment, and those with depression and with maltreatment [13].
Individuals who were depressed and maltreated were more likely to have higher levels of
CRP compared amongst depressed individuals only [13].
The biological etiology relates to the pathophysiology. A meta-analysis was
conducted to see the correlation between inflammation, the HP-axis, neurotrophic
growth, and vitamin D. There were 230 controls and 2,333 participants from the
Netherlands aged from 18-65 years old. Major depressive disorder (MDD) was grouped
into 8 different categories, ranging from familial risk to chronic MDD. The study showed
a linear increase of inflammatory markers (IL-6 and C-reactive protein), cortisol and a
decrease of vitamin D across the whole sample population. Trends of dysregulation were
found across stages for the at-risk individuals but not those who were in more progressive
stages of MDD [14].

8

Anxiety
Overview of Anxiety
Anxiety has been defined as an individual fearing that he or she will act in a way
that will be humiliating or embarrassing [4]. The National Comorbidity Study Replication
(NCS-R) assessed data for anxiety disorders that included: panic disorder; generalized
anxiety disorder; agoraphobia; specific phobia; social anxiety disorder; post-traumatic
stress disorder; obsessive-compulsive disorder; and separation anxiety disorder [15].
Females had a higher prevalence (23.4%) than males (14.3%) [15]. Those who were aged
30-44 had the highest prevalence (22.7%), followed by those aged 18-29 (22.3%), then
those 45-59 years old (20.6%), and finally those 60 or older (9.0%) [15]. A Dutch study
investigated potential risk factors for adolescents. Sex, socioeconomic status, parental
anxiety and depression, childhood adversity, temperament, body mass index, heart rate,
blood pressure, and cortisol were the variables included [16]. They found that female sex,
familial history, temperamental control, and low effortful control were significant
predictors for anxiety in adolescents [16]. Blanco et al. conducted a study to examine
whether the co-occurrence of anxiety disorders and MDD could be explained by an
underlying latent factor and whether the risk factors exert their effect exclusively through
this factor, directly on each other, or through a combination of effects at both levels [17].
It was concluded that low self-esteem, family history of depression, female sex,
childhood sexual abuse, white race, years of education number of traumatic experiences,
and disturbed family environment increased the risk of anxiety disorders and MDD
through their effect on the latent factor [17].
9

Pathophysiology
Individuals with an anxiety disorder have a high comorbidity rate with other
mood disorders including depression, and 90% of anxiety patients experience a form of
depression in their lifetime [18]. The FDA has approved selective serotonin reuptake
inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) for anxiety
treatment [19]. These drug classes are the same as the ones used for depression
medications. Anxiolytics like benzodiazepines can be used to minimize anxiety, but
dependence can occur using this drug [20]. These could be less likely to be prescribed in
comparison to SSRIs and SNRIs. Anxiety is one of the most common psychiatric
disorders. Anxiety disorders occur more frequently in women with an approximate ratio
of 2:1 [21]. Within the nervous system, there are specific mediators of anxiety which
include: norepinephrine, serotonin, dopamine, and gamma-aminobutyric acid (GABA)
[22]. The sympathetic nervous system mediates most of the symptoms [22].
The amygdala plays an important role in tempering fear and anxiety. Patients with
anxiety disorders have been found to show a heightened amygdala response to anxiety
cues like prefrontal cortex activation [22]. Common symptoms associated with anxiety
are either cognitive, physiological, behavioral, or affective symptoms [22]. Tricyclic
antidepressants, buspirone, and beta-blockers can also be treated to treat anxiety [22].
Persistent anxiety can also lead to cardiac events [22]. Since anxiety is fear-induced and a
part of the sympathetic nervous system, there is cortisol released in response. With
chronic cortisol release from anxiety, immunosuppression occurs [20].
COVID-19
10

COVID-19 Overview
SARS-CoV-2 is the causative agent of the coronavirus outbreak that occurred in late
2019 to early 2020. The disease as a result from SARS-CoV-2 infection is referred to as
COVID-19 and is an upper respiratory syndrome with vast symptoms. It can take around
5 days to develop symptoms after exposure to the virus [23]. Common symptoms of
COVID-19 are fever or chills, cough, shortness of breath or difficulty breathing, fatigue,
muscle or body aches, new loss of taste or smell, sore throat, congestion or runny nose,
nausea or vomiting, and diarrhea [23]. The virus has the capability to infect anyone, but
milder cases are generally seen in children and young adults. Those who are at higher risk
of becoming a case are those who are pregnant, older, have underlying chronic medical
conditions, have a substance abuse disorder, or are of Alaskan Non-Hispanic, American
Indian Non-Hispanic, Black Non-Hispanic, or Hispanic ethnicity [24]. Underlying
medical conditions that show a strong association include cancer [25], chronic kidney
disease [26], chronic obstructive pulmonary disease [27], heart conditions [28], severe
obesity with a BMI equal to or over 40 [29], pregnancy [30], sickle cell disease [31],
smoking [32], solid organ transplant [33], and type 2 diabetes mellitus [34]. Within
Kentucky, as of October 2021, the prevalence was approximately 16.5% [2].
Pathophysiology of COVID-19
The SARS-CoV-2 virus enters the cell by binding to the angiotensin-converting
enzyme 2 (ACE-2) [35]. This virus uses its spike protein on the outside of the cell to
recognize and bind to specific receptors on the host surface cell, resulting in virus entry to
the cell [36]. SARS-CoV-2 forms a complex with ACE-2 which is ten times more
11

significantly associated together for binding affinity than SARS-CoV [37]. This is
significantly greater than the threshold that is needed for the virus to cause disease [37].
There are studies that have shown that acute respiratory distress syndrome (ARDS) is the
leading cause of mortality in coronavirus disease [38]. A cytokine storm is an essential
mechanism of ARDS along with chronic unregulated systemic inflammatory stimulus,
which is an outcome of the release of many of the pro-inflammatory markers like IL-6,
tumor necrosis factor alpha, and interferon alpha [38]. Pathogen-associated molecular
patterns (PAMPs) can be seen by pattern recognition receptors (PRRs). SARS-CoV-2 can
stimulate a double-membrane vesicle synthesis, which possess no PRRs, and prevents the
host cell from detecting RNA [39]. Using this mechanism, it continues replication and
increases viral load and infection severity. In addition to being a respiratory disease,
COVID-19 has neurological implications. Some of these implications include dizziness,
headache, myalgias, hypogeusia, hyposmia, polyneuropathy, myositis, cerebrovascular
diseases, encephalitis, and encephalopathy [40].
Etiology of COVID-19
SARS-CoV-2 shares 88% of its viral genome with two bat-derived coronaviruses but
is more distant from SARS-CoV [41]. With the current data available, it appears that
SARS-CoV-2 may initially have been hosted within bats that transferred to a pangolin or
other wild animals sold at the Huanan market before spreading to humans [41].
Transmission from human-to-human contact is generally seen through breathing droplets
from sneezing or coughing from infected individuals. The SARS-CoV strain from 2003
has been shown to remain infective on surfaces for up to four days while other
12

coronaviruses have been detected up until nine days on surfaces [42, 43]. Studies have
shown that SARS-CoV2- can live on surfaces like stainless steel, plastic, glass, and
cardboard for at least several hours [44-46]. Fomites and surfaces could be another route
of transmission. The basic reproducibility, Ro, of this virus is between 2 and 3
consistently from data [47].
COVID-19 and Depression
With the emergence of COVID-19, social interactions have decreased, and many
people no longer participate as often in common social activities. With limited
interaction, depression and anxiety rates have increased. Etman et al. conducted a
studying to estimate the prevalence of and risk factors associated with depression
symptoms among US adults prior to and during the COVID-19 pandemic [48]. A
nationally representative study was conducted and used 2 population-based surveys of
US adults aged 18 and older. There were 1,441 participants that completed the COVID19 and Life Stressors Impact on Mental Health and Well-being survey. This survey was
conducted from March 21, 2020 to April 13, 2020. The prior prevalence for depression
symptoms were derived from the National Health and Nutrition Examination Survey
(NHANES) conducted from 2017 to 2018 [48]. The NHANES cohort had 5,065
participants. Depression symptom prevalence was 3-fold higher in all categories during
the beginning COVID-19 pandemic compared to before the pandemic. Higher risk of
depression symptoms during the COVID pandemic was associated with having a lower
income (OR: 2.37, 95% CI: 1.26-4.43), having less than $5,000 in savings (OR: 1.52,
95% CI: 1.02-2.26), and exposure to more stressors (OR: 3.05, 95% CI 1.95-4.77).
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A meta-analysis was conducted by Salari et al. looking at the prevalence of stress,
anxiety, and depression in the general population during the COVID-19 pandemic. The
systematic review and meta-analysis pulled articles from Science Direct, Embase,
Scopus, PubMed, Web of Science, and Google Scholar [49]. The meta-analysis found
that among 5 studies with a sample size of 9,074 that stress prevalence was 29.6% with
95% CI 24.3-35.4. The prevalence of anxiety among 17 studies with a sample size of
63,439 was 31.9% with 95% CI 27.5-36.7. The prevalence of depression among 14
studies with a sample size of 44,531 was 33.7% with 95% CI 27.5-40.6. This study shows
that there is a high prevalence of depression during the COVID pandemic with is
concordant with the work that Etman et al. performed.
Another study conducted by Mazza et al. examined the psychopathological impact
that being infected with COVID-19 has on survivors. There were 402 adults within the
cohort that were screened for psychiatric symptoms one-month after hospital treatment
[50]. A clinical interview and self-report questionnaires were used to investigate posttraumatic stress disorder (PTSD), depression, anxiety, insomnia, and obsessivecompulsive (OC) symptomology. Baseline inflammatory markers were also collected.
Overall, 56% scored in the pathological range for at least one clinical dimension, while
31% reported depression. Baseline inflammatory markers, screened through peripheral
lymphocyte, neutrophil, and platelet counts, were positively associated with scores of
depression and anxiety at follow-up showing that worsening inflammation with severity
of depressive symptoms.

14

A study conducted by Wiemken et al. looked at depression as a risk factor for
influenza severity for hospitalized adults. This study showed that non-elderly influenza
patients with depression were found to have 3.8% decreased adjusted risk of major or
severe loss of function compared to those without depression [51]. This was found to be
statistically significant with 95% CI of 1.9%-5.7% and a P-value < 0.0001. Overall, the
non-elderly patients with influenza infection, diagnosed with depression, had a decreased
risk of more severe disease and lower odds of inpatient mortality. The proposed
mechanism was that individuals who already have depression have increased proinflammatory cytokines. Death due to influenza is associated with increased
inflammatory response to infection rather than overwhelming infection itself. Those with
an increased inflammatory state may have negative regulatory networks which protect
against excessive inflammation.
These studies suggest that with the emergence of the COVID-19 pandemic depressive
symptoms have increased because of either the pandemic itself and isolation or through
directly contracting COVID-19. Depression as a risk factor needed to be explored, which
was the main objective of this study local to the Kentuckiana region.
Inflammation and Depression
The relationship between depression and inflammation is multifaceted. It has been
suggested that patients with inflammatory disease are more likely to show higher rates of
MDD, about one-third of people with MDD show elevated peripheral inflammatory
markers, and patients treated with cytokines are at increased risk for developing
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depression [52]. Inflammation is able to alter brain functioning and produces a pattern of
symptoms known as sickness syndrome which mirrors depression [53].
Depression with Inflammatory Outcomes
A study conducted by Duivis et al in the Netherlands explored depressive
symptoms and inflammatory markers through interleukin-6, C-reactive protein (CRP),
and tumor necrosis factor [54]. There were 2,861 participants aged from 18-65 years old.
There were 2,231 participants with current or past depression and/or anxiety diagnosis
and 630 controls. The study was designed as a cohort with linear regression as the acting
analysis accounting for age, sex, educational years, cardiovascular disease, diabetes,
medication type, smoking status, alcohol intake, body mass index (BMI), and physical
activity. When adjusting for demographics and health indicators, IL-6 and CRP were
found to be statistically significant with a p-value <0.001 while the tumor necrosis factor
was statistically significant with a p-value of 0.018 among those with a history of
depression and/or anxiety compared to controls.
Another study conducted by Stewart et al. explored the effect on depressive
symptoms and inflammatory outcomes. This study was a prospective cohort set in
Pittsburgh with 263 participants aged 50-70 years old [55]. The covariates used in this
study were age, sex, race, education level, smoking status, daily alcohol intake, BMI,
high density lipoprotein cholesterol, triglycerides, fasting glucose, fasting insulin,
diabetes, rheumatoid arthritis, and physical activity. Depressive symptoms were
measured through the Beck Depression Inventory II questionnaire (BDI-II). Inflammation
was assessed by measurement of IL-6 and CRP levels, at three different time points over
16

six years. One of the three data sets was not analyzed due to a clerical error. It was found
that greater depressive symptom severity at baseline was associated with a larger 6-year
increase in serum IL-6. In the studies’ entirety, IL-6 and CRP were not associated with
depressive symptoms measured by BDI-II .
Inflammation with Depression Outcomes
The other possibility is inflammation causing depression. Krogh et al. investigated
the impact of exercise intervention on major depression in a cohort study with 169
participants [56]. Of these participants, 112 were diagnosed with MDD and 57 were
health controls. At baseline, cytokines were measured as well as depression through the
Hamilton depression rating scale. The participants with MDD were then randomized to
either a 3-month exercise program or an attention control group performing low impact
exercises. IL-6 and high-sensitivity CRP were the inflammatory makers measured. Age,
sex, depression status, and education were the confounders assessed through the linear
regression model. The results showed that overall, those with higher depressive
symptoms had higher levels of high-sensitivity CRP and IL-6. Once controlling for
lifestyle factors, the difference was no longer significant.
A study conducted by Lindqvist et al. explored oxidative stress and inflammation
and their association with major depressive disorder. In this prospective cohort, there
were 105 participants and tested to see response to antidepressants and inflammation
markers among those unmedicated for major depression disorder and controls [57]. The
inflammatory markers quantified in this study included IL-6, tumor necrosis factor, CRP,
F2-isoprstanes, 8-OH 2-deoxyguanosine, glutathione peroxidase, glutathione, and
17

vitamin C. Controlled variables included sex, age, BMI, and smoking. Baseline blood
samples were collected in addition to blood samples at 8 weeks after treatment and the
participants were scored on the Hamilton Depression Rating Scale at both time points.
Participants who were diagnosed with major depressive disorder showed higher levels of
IL-6 (p<0.001), tumor necrosis factor (p<0.001), 8-OH 2-dexoyguanosine (p=0.018), and
F2-isoprostanes (p=0.012). Those who were non-responders to the SSRI treatment had
higher F2-isoprostanes at baseline (p=0.006) and after 8 weeks of treatment (p=0.031)
compared to responders. Non-responders in the study showed an increase in 8-OH 2deoxyguanosine (p=0.021 over the course of the study while responders showed a
decrease in IL-6 levels (p=0.019).
Antidepressants and the Immune System
There has been a relationship established with depression and inflammation, but there
are effects from antidepressants that play a role on the immune system as well. The
interactions between the nervous system and immune systems are the main issue
addressed by psychoneuroimmunology [58]. It has been suggested that antidepressants
modulate immune response. One way they do this is by affecting the activation,
proliferation, and survival of leukocytes [58]. The immunosuppressive effect of the HPA
axis seems to be insufficient to reduce inflammation associated with depression, which
can decrease the threshold of hypothalamic sensitivity to pro-inflammatory cytokines
[59]. Antidepressant drugs are believed to have immunomodulatory properties as well as
functioning as neurotransmitter transporters [58]. A study conducted by Dahl et al.
measured blood cytokine levels before and after 12-week antidepressant therapy in 50
18

patients [60]. There was a significant reduction in the levels of cytokines, interleukin-6
and interferon gamma, from the baseline measure but did not significantly differ from the
patients who were controls. Over the course of the study, 43 participants completed it and
30 were found to meet the recovered criteria. Those who met that criteria were the
individuals who had statistically significantly reduced cytokines compared to their
baseline measure. The 13 participants who did not meet the recovery criteria did not have
statistically reduced cytokines compared to their baseline measure.
Other studies have shown contrary effects seen by Dahl et al. A study that treated in
vitro of whole blood cultures with selective serotonin reuptake inhibitors (SSRIs) and
mirtazapine, tetracyclic antidepressant, increased the production of cytokines [61].
Interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha all showed increased
inflammatory markers when measured while being treated with those drugs.
Chen et al. assessed the effect of antidepressants on plasma cytokines in 91 MDD
patients compared to 90 healthy controls in a case-control study. Baseline plasma
cytokines were measured in controls and patients, while patient’s cytokines were also
measured after completing the 8-week treatment of either venlafaxine or paroxetine [62].
After 8 weeks of treatment, the mean interferon gamma, tumor necrosis factor, IL-4, IL5, and IL-8 were significantly lower in the venlafaxine group than the paroxetine
(p<0.001). Paroxetine was found to increase the levels of IL-6 (p=0.003) the most in the
non-remitter, those who were not in remission, group (n=29) than the remitter group
(n=21).
Anxiolytics and the Immune System
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Inflammation has been implicated in the pathogenesis of depression and anxiety.
In a prospective cohort study with 42 participants conducted by Hou et al., the effects of
SSRIs on peripheral cytokines in patients with first episode generalized anxiety disorder
was investigated [63]. The patients were 18-60 years old, BMI between 18 and 30, 6 or
more years of education, and a primary diagnosis of the first episode of general anxiety
disorder. These patients did not have a history of taking either antidepressants or
anxiolytics. Treatment lasted 12 weeks with either escitalopram (n=28) or sertraline
(n=14). A sample of 10 mL of blood was taken before treatment at approximately the
same time of day. The blood was analyzed for IL-1β, IL-6, IL-8, IL-12p70, and IFN-γ by
an enzyme linked-immuno-absorbent assay. CRP was measured through immunological
transmission turbidity. The same measure occurred 12 weeks after treatment. Anxiety
was measured through the Generalized Anxiety Disorder Scale (GAD-7) and State Trait
Anxiety Inventory.
For data analysis, treatment response was defined as a reduction in the GAD-7
score, differential between pre- and post-treatment, equal to or greater than 50%. No
treatment response was defined as less than 50% reduction in the GAD-7 score. While
controlling for BMI, smoking, and alcohol consumption, logistic regression on logtransformed CRP and IL-6 had a significant predict value for treatment response. While
controlling for the same variables in either a Pearson or Spearman correlation model, it
was demonstrated that there was a significant positive correlation between change in
anxiety and change in peripheral inflammatory markers (p < 0.05). This finding
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demonstrates patients with a greater reduction in anxiety also had a greater reduction in
cytokine levels.
Costello et al. performed a systematic review and meta-analysis of the association
between peripheral marks of inflammation and generalized anxiety disorder. The sources
that were used were MEDLINE, EMBASE, PsycINFO, and Web of Science [64]. The
eligibility criteria in this analysis were primary, quantitative research studies of people
with a diagnosis of GAD assessed using a standardized clinical interview that measured
peripheral inflammatory markers. Of the 1,718 studies identified, 14 of those met the
criteria. The primary reason studies were rejected was due to the lack of diagnosis of
GAD was recorded or inflammatory marker was measured. There were 1,118 patients
with GAD with 10,623 controls. There were 16 cytokines evaluated. CRP (9/14), TNF- α
(6/14), IL-6 (5/14), and IFN-γ (3/14) were the most common cytokines among this data
set. The other cytokines were only analyzed in 2 or less studies. Significantly raised
levels of CRP, IFN-γ, and TNF- α were reported in patients with GAD compared with
controls in two or more studies. Ten further proinflammatory cytokines were reported to
be significantly raised in GAD in at least one study. Five of the 14 different studies found
no difference in the levels of at least one cytokine. CRP was the only cytokine with
sufficient data for meta-analysis. It was found that CRP was significantly higher in
people with GAD compared with controls.
Conclusion
These studies suggest that depression is associated with higher levels of
inflammatory markers (IL-6 and CRP) and that inflammation can increase the risk of
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depression. Cytokine storms have been showed to induce ARDS in patients with COVID19. It has also been shown that antidepressants can either raise or lower cytokine levels.
There are studies showing how COVID-19 induces depression, but there are no studies
investigating depression as a risk factor of COVID-19 mortality or severity in the
Kentuckiana region. Individuals with other inflammatory diseases like autoimmune
diseases are at higher risk for more severe outcomes from COVID-19 disease; therefore,
individuals with depression could be as well. This study will fill a gap in the literature by
evaluating the association between depression and COVID-19 outcomes.
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IV. METHODS
Study Design:
The data used in this study came from the Burden of COVID-19 study (Granting
institution: University of Louisville; Principal Investigator: Dr. Julio Ramirez; IRB #200257). The purpose of the Burden of COVID-19 study was to assess the incidence,
epidemiology, and clinical outcomes of patients in Kentuckiana diagnosed with COVID19 [65]. The retrospective data was collected from Electronic Medical Records (EMR)
from March-July 2020 within the hospital network in Kentuckiana [65].
Study Population:
The study population was located within the Kentuckiana region, focused on
Louisville, KY and the surrounding areas. The Center for Excellence for Research in
Infectious Diseases (CERID) at the University of Louisville maintains a retrospective
cohort study of hospitalized patients infected with SARS-CoV-2 [66]. There were nine
acute care hospitals located within Louisville, Kentucky [66] with 698 patients for the
time period March 7th, 2020 to July 6th, 2020. Patients 18 years and older and who tested
positive for SARS-CoV-2 by Polymerase Chain Reaction (PCR) test and admitted into
the hospital were included.
Data Collection:
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Reverse Transcriptase-Polymerase Chain Reaction testing was performed either
by the University of Louisville Division of Infectious Diseases reference laboratory or at
the associated lab of each hospital [66]. The CEIRD research team performed daily
screenings of the hospital’s EMR or from a daily report sent by the hospital to determine
which patients had a confirmed or presumptive COVID-19 diagnosis. [66]. Information
that was ascertained through either EMR or the daily report included COVID-19 test
results; demographic and hospitalization data; past medical and social history; current
medications; signs and symptoms; physical examination; laboratory, radiologic and
microbiologic findings; management and therapies; in-hospital complications; and
clinical outcomes [66].
Outcome Assessment:
Discharge status, either alive or dead, was extracted from the EMR and used to
assess COVID-19 mortality. Time to death was evaluated by the date admitted into the
hospital until date of death. COVID-19 severity was evaluated by ventilation and
placement in the ICU. Both ventilation and ICU admission, were assessed as
dichotomous variables, either receiving said treatment or not. Time on ventilation or time
in ICU was not assessed.
Exposure Assessment:
The EMR listed the various depression medications, which included both brand
name and generic drugs. These drugs were assessed separately based on active drug
ingredient. The terms for SSRIs used to search the dataset were Celexa, citalopram,
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Lexapro, escitalopram, fluoxetine, paroxetine, Zoloft, sertraline, vortioxetine, Viibryd,
and vilazodone. For SNRIs the dataset search terms t were Cymbalta, duloxetine,
desvenlafaxine, venlafaxine, and Savella. TCAs within the dataset were searched for
using the terms amitriptyline and doxepin. Additional antidepressant medications not
listed within those drug classes were searched for using the terms Wellbutrin, bupropion,
Remeron, mirtazapine, and trazodone.
The medication class that was assessed for anxiety was benzodiazepines. The
terms used to search within the dataset for benzodiazepines were alprazolam, clobazam,
clonazepam, Diazepam, Ativan, lorazepam, and triazolam. The terms used to identify
additional anxiolytics within the dataset were buspirone, Vistaril, hydroxyzine, prazosin,
and pregabalin. An anxiety diagnosis was also determined by a recent diagnosis which
was outlined by the CERID research team.
Some of the medications that were prescribed within this dataset for both anxiety and
depression can be used for either diagnosis. Thus, it was not possible to accurately
separate the diagnosis by the EMR, so a combined variable was created within this
dataset for both depression and anxiety diagnosis. Exposure status was defined as having
taken either medication or having either a depression/anxiety diagnosis. Duration of
diagnosis of either depression or anxiety was not determined.
Confounding Assessment:
A confounding assessment was performed before interaction. Confounding was
evaluated by removing a covariate from the full model and assessing whether there was a
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10% difference in the reduced model’s exposure odds ratio compared to the full model’s
exposure odds ratio. If there was a 10% difference, then the variable was considered a
confounder. If the covariate was close to a 10% difference and the 95% confidence
intervals were tighter than the full model’s 95% confidence intervals, then the covariate
was considered a confounder and kept within the model. Relevant covariates were chosen
based on a directed acyclic graph (DAG) (Figure 1), which was guided by the literature
review. The initial list of potential covariates included age, race, sex, BMI, smoking
status, alcohol abuse, diabetes, asthma, and COPD.

Figure 1: Directed Acyclic Graph

Potential Mediation and Effect Modification:
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Mediation and effect modification were assessed through inflammatory markers
IL-6 and CRP levels between inflammation and depression and/or anxiety. Both
inflammatory markers were analyzed through a sub-population as not every participant
had data listed for these markers. Both markers had their concentration log-transformed
to achieve a more normal distribution while running logistic regression for assessment.
Mediation was assessed by comparing the difference between the inflammatory model to
the odds ratio of a logistic regression model with the inflammatory marker to the odds
ratio of a logistic model without the marker. Effect modification was assessed by adding
an interaction term into the model. The interaction term consisted of the exposure
multiplied by the inflammatory marker. If the p-value was less than 0.05 then it was
concluded that there was interaction between the inflammatory marker and exposure on
the outcome of interest.
Data Analysis:
Descriptive Statistics:
All of the analyses for this thesis were conducted in SAS 9.4. Descriptive
statistics were calculated for the covariates to examine their distributions within this
dataset. Univariate analyses were performed to examine the crude association between
the covariates and the exposure. Student’s T-test was used for normally, distributed
continuous variables while the Chi-square test was used for categorical variables. The
covariates that were included in the final multivariable models were chosen by data-based
and theory-based methods. Covariates from the DAG that had an association with the
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exposure with a p-value less than 0.1 were initially included in the multivariable model.
Age and sex were included in the model regardless based on available literature.
Multivariable Models:
Logistic Regression:
The effect of depression, anxiety, or both was analyzed on mortality, ventilation,
and ICU admission using separate multivariable logistic regression models. The models
were evaluated for multicollinearity prior to confounding and interaction assessment.
There were no issues with multicollinearity found in any of the models. To choose the
remaining covariates, confounding was assessed prior to interaction because of the
inability to explain biological pathways. Confounding was assessed by comparing the
exposure’s odds ratio of the full model to the exposure’s odds ratio of a reduced model,
which had one covariate removed. If there was more than a 10% change in the exposure’s
odds ratio or it was approaching a 10% difference and the 95%confidence intervals
became narrower, then the variable was considered a confounder. Interaction was
assessed by adding an interaction term to the final model used for analysis. The
interaction term consisted of the exposure multiplied by the covariate of interest. If the pvalue for the interaction term was less than 0.05, then it was concluded that there was
interaction between the exposure and covariate on the outcome of interest. No
statistically significant interactions were found between the covariates and the exposure.
Covariates that were chosen for these different models, based on the criteria described
above, were sex, age, and chronic obstructive pulmonary disease (COPD).
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Mediation and effect modification were assessed using the different subsets based
on available data for CRP and IL-6. Both inflammatory markers were log transformed to
achieve a more normal distribution. The model that was used to assess mediation and
effect modification was the final model for mortality. Mediation was assessed by adding
the inflammatory marker to the model to examine the difference in the exposure’s odds
ratios of the regression models. The extent of mediation was evaluated by the percentage
different between the exposure’s odds ratio from the model including the inflammatory
marker compared to the exposure’s odds ratio from the model without the inflammatory
marker. Effect modification was assessed by using an interaction term within the models.
The interaction term used within the model was the exposure multiplied by either IL-6 or
CRP. If there was a p value < 0.05 for the interaction term, then it was concluded to be an
effect modifier.
Survival Analysis – Cox Proportional Hazards Regression Model:
A Cox proportional hazards model was used to conduct a survival analysis. The
participants had a hospital admission date, hospital discharge date, discharge outcome,
and death date recorded within their EMRs. The start time within this model was defined
as the date of hospital admission and the stop time was either date of death or discharge
status being alive. The proportional hazards assumption test was conducted to assess
whether the PH assumption was met. If it was not met, Heaviside functions were used
with an extended Cox model. Censorship was determined by survival while being
discharged from the hospital and an event was death defined by the date of death. The
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same covariates that were used within the logistic regression models were used within
this model for consistency.
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V. RESULTS
There were 922 participants enrolled from March 1st, 2020 to July 6th, 2020.
Among those, 224 were excluded: 106 for being younger than 18, 114 for not being
admitted to the hospital, and 4 for missing data on height, which was used for BMI
calculation. There were 698 participants used for data analysis.
Descriptive Statistics
Among the 698 participants, 204 (29.2%) were diagnosed with either depression
and/or anxiety. Table 1 shows the sample population stratified by depression or anxiety.
Those who were diagnosed were more likely to be older (P= <0.0001), white (P=
<0.0001), female (P = <0.0001), smokers (P = 0.0002), and have a higher BMI (P =
0.0265). Examining comorbidities, those with depression and/or anxiety were more likely
to be diagnosed with diabetes (P = 0.0006); COPD (P = <0.0001); hypertension (P =
<0.0001); hyperlipidemia (P = <0.0001); renal disease (P = 0.0035); and a prior cardiac
event, which was defined as being diagnosed with either coronary artery disease, heart
failure, atrial fibrillation, myocardial infarction, or deep vein thrombosis (P = <0.0001).
Alcohol abuse (P = 0.67); asthma (P = 0.48); neoplastic disease (P = 0.16); and history of
obstructive sleep apnea (P = 0.18) were not significantly associated with depression
and/or anxiety.
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Table 1. Patient Demographics and Medical History (n=698).

N=698
Demographic Characteristics
Age, years (mean(SD))
18-44 (N, %)
45-60 (N, %)
61-73 (N, %)
74-102 (N, %)
BMI, kg/m2 (mean(SD))
Healthy
Overweight
Obese
Morbidly Obese
Race (N, %)
White
Black
Other
Sex (N, %)
Female
Male
History of Smoking (N, %)
Never
Current
Former
Alcohol Abuse (N, %)
No Alcohol Abuse
History of Alcohol Abuse
Comorbidities
Diabetes (N,%)
Asthma (N, %)
COPD (N, %)
Hypertension (N, %)
Hyperlipidemia (N, %)
Neoplastic Disease (N, %)
Renal Disease (N, %)
History of Obstructive Sleep Apnea (N, %)
Prior Cardiac Event (N, %)
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Without either
Depression or
Anxiety

With either
Depression or
Anxiety

494

204

P-valuea

55.3 (18.8)
159 (32.2)
136 (27.5)
112 (22.7)
87 (17.6)
31.5 (8.6)
111 (22.5)
132 (26.7)
116 (23.5)
135 (27.3)

69.2 (15.3)
13 (6.4)
38 (18.6)
65 (31.9)
88 (43.1)
30.1 (8.8)
67 (32.8)
45 (32.1)
37 (18.1)
55 (27.0)

<0.0001

241 (48.8)
169 (34.2)
84 (17.0)

140 (68.6)
49 (24.0)
15 (7.4)

<0.0001

245 (49.6)
249 (50.4)

137 (67.2)
67 (32.8)

<0.0001

344 (69.6)
48 (9.7)
102 (20.7)

110 (53.9)
23 (11.3)
71 (34.8)

0.0002

458 (92.7)
36 (7.3)

191 (93.6)
13 (6.4)

0.67

142 (28.7)
47 (9.5)
47 (9.5)
234 (47.4)
139 (28.1)
29 (5.9)
75 (15.2)
40 (8.1)
124 (25.1)

86 (42.2)
23 (11.3)
54 (26.5)
137 (67.2)
98 (48.0)
18 (8.8)
50 (24.5)
23 (11.3)
84 (41.2)

0.0006
0.48
<0.0001
<0.0001
<0.0001
0.16
0.0035
0.1828
<0.0001

<0.0001
0.0550
0.0265

a

Categorical variables were assessed with the Chi-square test of independence.
Continuous, normally distributed variables were assessed with Student’s t-test.
Medication Frequency
There were 242 different instances where an antidepressant medication was
reported, which includes the ones listed as miscellaneous. Citalopram/escitalopram (37)
Sertraline (30), and Mirtazapine (32) were the most frequently used antidepressants
among the patients (Table 2). There were 78 different instances were an anxiolytic
medication as used, including the ones listed as miscellaneous. Lorazepam (16),
Alprazolam (14), Hydroxyzine (13), and Clonazepam (11) were the most frequently used
anxiolytics (Table 2). There were some name-brand and generic antidepressants and
anxiolytics that were not taken but included within the medication list used by the
Infectious Disease Department to search within the EMRs.
Table 2. Medication Frequency.
Medication
Frequency
Antidepressants
SSRIs (Selective Serotonin Reuptake
Inhibitor)
Citalopram/Escitalopram
37
Sertraline
30
Fluoxetine
11
Lexapro
5
Paroxetine
4
Prozac
3
Celexa
2
Zoloft
2
Vortioxetine
1
Viibryd
1
Vilazodone
1
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SNRIs (Serotonin-norepinephrine
Reuptake Inhibitor)
Venlafaxine/Desvenlafaxine 12
Duloxetine
12
Cymbalta
4
Savella
1
TCAs (Tricyclic Antidepressants)
Amitriptyline
16
Doxepin
2
Miscellaneous
Mirtazapine
Trazodone
Quetiapine
Bupropion
Wellbutrin
Seroquel
Remeron

32
21
16
16
8
4
1

Anxiolytics
Benzodiazepines
Lorazepam
Alprazolam
Clonazepam
Ativan
Diazepam
Clobazam
Triazolam

16
14
11
4
3
1
1

Miscellaneous
Hydroxyzine
Buspirone
Pregabalin
Prazosin
Vistaril

13
6
5
3
1

The list of antidepressants or anxiolytics were also examined within this data set.
For those taking either an antidepressant or anxiolytic, there were 122 patients taking one
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medication; 56 were taking two medications; 17 were taking three medications; and 9
were taking four medications (Table 3).
Table 3. Number of Antidepressants or Anxiolytics per Patient.
Number of Medications
Frequency
1
122
2
56
3
17
4
9

Specific Aim 1: To evaluate the association between depression and COVID-19
severity.
The exposure of having a history of depression and/or anxiety was not
significantly associated with ICU admission (OR: 1.01, 95% CI: 0.69-1.46) or with
ventilation (OR: 1.19, 95% CI: 0.78-1.181) (Table 4). To further understand the clinical
implications of the effect of depression/anxiety on mortality, the mortality model was
stratified by ICU admission and interaction was assessed. Interaction between
depression/anxiety and ICU admission did not yield a p-value <0.05 for statistical
significance (p-value: 0.090). For those with depression/anxiety and did not enter the
ICU, statistical significance was seen for association with mortality (OR: 5.18, 95% CI:
1.81-14.86) (Table 5). Once in the ICU, there was not a statistical significance between
those with or without depression/anxiety (OR: 1.83, 95% CI: 0.98-3.40) (Table 5). This
could be due to the fact that once one is admitted to the ICU, there is a higher mortality
rate overall and comorbidities do not have much of an effect.
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Specific Aim 2: To evaluate the association between depression and COVID-19
mortality and time to death.
History of depression and/or anxiety was associated with mortality due to
COVID-19 (OR: 1.84, 95% CI: 1.15-2.93) (Table 4). Among those who were not
admitted into the ICU, 12.6% of the patients who were depressed died compared to the
1.6% who were not depressed (Table 5). Those who were admitted into the ICU, 46.8%
of those who were depressed died compared to the 28.4% who were not depressed (Table
5). To determine the effect of history of depression and/or anxiety on time to death, a Cox
proportional hazards model was used. The Kaplan-Meier curves were significantly
different by the log-rank test (p=0.0022) (Figure 2). While examining the log-negative
log survival curve to test the PH assumption, the graphs appeared mainly parallel and
were concluded to meet the PH assumption (Figure 3). A Goodness of Fit statistical test
was conducted, and the residuals were not correlated with time, also providing evidence
that the PH assumption was met. Taking medications for depression and/or anxiety was
associated with time to mortality, after adjusting for age, sex, and history of COPD (HR:
1.60, 95% CI:1.07-2.39) (Table 4).
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Table 4. Association Between Depression/Anxiety and COVID-19 Outcomes.
Outcome

ORa,b/HRc

Mortality
1.84b
Ventilation
1.19b
ICU
0.95b
Time to Mortality
1.60c
a
Adjusted for age, sex, and history of COPD.
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95% Confidence
Interval
1.15-2.93
0.78-1.81
0.66-1.39
1.07-2.39

P value
0.01
0.42
0.95
0.02

b
c

Odds Ratio
Hazard Ratio
Table 5. Mortality Outcomes Stratified by ICU Admission
Without
With Depression
ICU Admission
Depression or
or Anxiety
Anxiety
Not admitted
Alive (N,%)
306 (98.4)
111 (87.4)
Deceased (N,%)
5 (1.6)
16 (12.6)
Admitted
Alive (N,%)
131 (71.6)
41 (53.3)
Deceased (N,%)
52 (28.4)
36 (46.8)
Multivariable
Model
OR
95% CI
Stratified by ICU
Not admitted
5.18
1.81-14.9
Admitted
1.83
0.98-3.40

P value

<0.0001

0.0043
P value
0.0022
0.057

Specific Aim 3: To evaluate if inflammation, assessed through levels of the
inflammatory markers IL-6 and CRP, acts as an effect modifier or mediator on the
association between depression and COVID-19 mortality.
Different sub-populations were created and used for each inflammatory marker
because the data for the inflammatory markers was not completed for all 698 participants.
The same variables were retained as those for the logistic regression models. Only the
mortality regression model was used to assess both sub-populations for both mediation
and effect modification.
IL-6 mediation was evaluated by adding it to the model. There was about a 5%
decrease in the odds ratio for the effect of depression and/or anxiety on mortality when
IL-6 was added to the model. Effect modification was assessed by adding an interaction
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variable between the exposure and IL-6. It was not found to be statistically significant, so
no effect modification was determined (P = 0.16) (Table 6).
CRP mediation was evaluated by the same processes. There was about a 4%
increase in the odds ratio for the effect of depression and/or anxiety on mortality when
CRP was added to the model. Effect modification was assessed in the same fashion as
stated above. It was not found to be statistically significant, so no effect modification was
determined (P = 0.23) (Table 6).
Table 6. Effect of IL-6 and CRP Levels on the Association Between Depression and/or
Anxiety and Mortality.
Inflammatory
Marker
IL-6 (N=201)
CRP (N=457)

OR
Inflammatory
95% CI
Marker
Adjusted-No
1.98
0.86-4.51
1.83
1.03-3.25
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OR
Inflammatory
Marker
Adjusted-Yes
1.88
1.91

95% CI
0.77-4.45
1.07-3.41

Effect
Modification Pvalue
0.16
0.23

VI. DISCUSSION
This study’s objective was to assess the effect of depression and/or anxiety on
COVID-19 severity outcomes and mortality. Overall, depression and/or anxiety were not
associated with ICU admission or ventilation. However, depression and/or anxiety were
associated with mortality, with 84% higher odds of mortality, after adjusting for age, sex,
and history of COPD (95% CI: 1.15-2.93). History of depression and/or anxiety were
associated with time to mortality with 60% higher odds of mortality after adjusting for
age, sex, and history of COPD (95% CI: 1.07-2.39). There was no meaningful mediation
concluded or effect modification found for either IL-6 or CRP.
Depression and/or Anxiety and COVID-19 Outcomes
Although no significant associations were found between depression and/or
anxiety and ICU admission or ventilation, there was a significant association with
mortality and time to mortality due to COVID-19. Those who were diagnosed with
depression may have been less likely to seek out treatment and to have experienced
disease progression by the time treatment was sought. In this dataset of individuals
hospitalized with COVID-19, approximately 29% were depressed overall; however, of
those who died, about 48 % were depressed. Additionally, there seemed to be an inverse
association with ICU admission; of those who died and were not admitted into the ICU,
about 76% of those patients were depressed. For those who died and did not receive
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ventilation, about 58% of those patients were depressed. These data suggest that
depression and/or anxiety increases risk of mortality regardless of ICU admission or
ventilation.
These findings are in keeping with a 2020 U.K cohort study, which reported that a
pre-pandemic depression diagnosis was significantly associated with mortality (aOR:
2.67, 95% CI: 2.03-3.54) [67]. Another 2020 study based on electronic record data
reported a higher death rate (8.5%) for COVID-19 patients with a recent diagnosis of a
mental disorder compared with COVID-19 patients with no evidence of a mental disorder
(4.7%), and more so when compared with patients with no COVID-19 infection and no
mental disorder diagnosis (1.4%) [68]. A meta-analysis of studies examining preexisting mental disorders found that mood disorders were significantly associated with
mortality among those with a SARS-CoV-2 infection (OR: 1.99, 95% CI: 1.46-2.71), but
antidepressant use was only significant in models with no adjustment for potential
confounders [69]. Anxiety disorders were not associated with an increased risk of
mortality (OR: 1.07, 95% CI: 0.73-1.56), but anxiolytic use was (aOR: 1.47, 95% CI:
1.15-1.88) [69]. No increased risk of ICU admission was found in this meta-analysis for
those with a mental disorder (aOR: 1.33, 95% CI: 0.87-2.04) [69]. The meta-analysis also
concluded that those with severe mental disorders had higher COVID-19 mortality
estimates (aOR: 1.55 95% CI:1.30-1.85) compared to patients with other mental disorders
(aOR: 1.09, 95% CI: 0.92-1.29) [69]. Overall, this evidence suggests that the effect of
depression and/or anxiety on COVID-19 mortality may be increased for those actively
taking medication or with a severe mental illness diagnosis.
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Depression and/or Anxiety and Inflammatory Markers
There was no significant effect modification found by either inflammatory marker
on the effect of depression and/or anxiety with COVID-19 mortality. Some mediation
was seen from both markers. Including IL-6 in the multivariable model decreased the
effect of depression and/or anxiety on mortality, while including CRP increased the effect
of depression and/or anxiety on mortality. The mediation seen by IL-6 is not what has
been seen in some previous studies [54, 55, 70], but the mediation by CRP does relate to
previous studies [54, 55, 70]. Other studies have shown that antidepressants decrease
cytokine activity like IL-6 [60, 62]. By decreasing cytokine activity through
antidepressant medication, this could reduce the potential for a cytokine storm, which
would lead to ARDS and death [36] therefore, potentially explaining the reduced effect
on the association of depression and/or anxiety on mortality. Both inflammatory markers
were significantly associated with COVID-19.
Strengths and Limitations
This study has multiple strengths. First, this is one of the few studies to explore
the effect that depression and/or anxiety has on COVID-19 outcomes in the Kentuckiana
region. This is also the first study to assess mediation and effect modification by IL-6 and
CRP. This study will add to the developing literature and lead to discussions about the
biological pathways that could lead to such associations.
Another strength was the use of PCR to identify those with a SARS-CoV-2
infection. Using this tool, it reduced misclassification on those admitted into the hospital
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with a COVID-19 diagnosis. One final strength of this study is the region. Kentucky is a
good place for this study having a vaccination rate of 51.7% and within the 10-14.9% 7day positivity rate for COVID-19 compared to the United states average of 6.18% [71]. A
recent study reported depression within Kentucky at 28.6% while the United States
prevalence was 7.8% [3, 8]. This study assists doctors within the region to understand the
possible consequences of depression and anxiety which may lead to adjusting the
treatment of those who are hospitalized with COVID-19. Treatment could be altered by
screening for depression/anxiety and observing severity symptoms to treat those
symptoms sooner.
There are limitations in this study that should be noted. Mental health diagnoses
were classified based on only medication use as reported in the EMR, which may have
resulted in misclassification. Cases of depression or anxiety as well as prescribed
medication may have been missed. For example, some patients within this study could be
misclassified by not having depression or anxiety but could have the diagnosis while not
actively taking medicine. Other participants may have been actively taking the
medication, but it was not listed within the EMR. The medication list may not have been
extensive enough to include all possible medications.
The population was restricted to those who were hospitalized, affecting external
validity because we were not able to examine the effect of depression and/or anxiety on
the risk of COVID-19 infection. Differential misclassification could occur with mortality
by misclassifying the cause of death. A third limitation is that literature was emerging
while this study was progressing, and residual confounding may be present given the
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limited number of studies with sufficient duration to assess the influence of a large
number of covariates.
Future Research
Since the emergence of SARS-CoV-2 and the beginning of this study, different
screening tools have been developed and implemented. Testing sites are more widely
available and accessible for more screening opportunities. With these screening
opportunities, both symptomatic and asymptomatic patients could be recruited for a
prospective cohort study. Once enrolled based on a positive SARS-CoV-2 PCR result,
questionnaires regarding symptoms and mental health status could be administered. This
would expand the sampling population to outside of just those hospitalized, and address
classification of individuals based on mental health status. Further research is also needed
to understand the biological pathway to explain the association between depression
and/or anxiety and mortality. This would allow for research opportunities to examine the
effect of depression on less severe COVID-19 outcomes such as being symptomatic
versus asymptomatic and risk of hospitalization.
Conclusion
COVID-19 remains a significant public health concern as recent and on-going
studies provide evidence of an association between depression/anxiety and COVID-19
outcomes. This literature is still developing as COVID-19 long-term effects and
mechanisms are being discovered.
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From this study, it was concluded that there was an association between
depression and/or anxiety with mortality and time to mortality from COVID-19
diagnosis. There was no association concluded with depression and/or anxiety with ICU
admission or ventilation. There was no meaningful mediation found from either IL-6 or
CRP on the effect of depression and/or anxiety and mortality. There was no effect
modification by inflammatory markers on depression and/or anxiety. These results will
add to the evolving literature on the association of mental disorders and COVID-19
outcomes and can be built upon for future research with different methods and
developing technologies.
.
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